Abstract
Advances in immunotherapy have already been achieved with checkpoint inhibitors to enhance T cell responses such as inhibition of PD-1/PDL-1 in solid tumors and lymphoproliferative diseases, with promising results, and more scarce data from clinical trials in myeloid leukemias, as well as with Genetic Engineering of T lymphocytes (CAR-T cell therapy). However, for myeloid diseases, this t…